Table 2 Characteristics of the studies included in meta-analysis
Country | Mean age | Male(%) | Sample size | detection index |
|---|---|---|---|---|
China [8] | NA | 35 (57.4%); NA | IgAN 61; Healthy Control 65 | C1GALT1 expression |
China [9] | 14.68; 9.04; 13.27 | 12 (52.1%); 5 (20%); 17 (73.9%) | IgAN 23; Control 33(Non- IgAN 10; Healthy Control 23) | C1GALT1 expression |
UK [10] | 44.5; 37 | 10 (83.3%); 7 (53.8%) | IgAN 12; Non- IgAN 13 | C1GALT1 expression and β1, 3Gal-T activity |
UK [11] | 51.2; 43 | 3 (60%); 2 (40%) | IgAN 5; Healthy Control 5 | C1GALT1 expression |
UK [12] | 33; 38 | 6 (66.6%); 6 (50%) | IgAN 9; Healthy Control 12 | β1, 3Gal-T activity |
China [5] | 27.53; 29.4; 25 | 14 (34.1%); 7 (33.3%); 9 (56.2%) | IgAN 41; Control 37 (Non- IgAN 21; Healthy Control 16) | C1GALT1 expression |
China | 38; 37 | 16 (53.3%); 15 (50%) | IgAN 30; Healthy Control 30 | C1GALT1 expression and Gd-IgA1 levels |